IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model. Issue 5 (16th April 2019)

• Record Type: Journal Article
• Authors: Wu, Xuesong; Hsu, Daniel K.; Wang, Kang-Hsin; Huang, Yuanshen; Mendoza, Lindsay; Zhou, Youwen; Hwang, Sam T.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 5(2019)
• Page Start: 1244
• Page End: 1252
• Publication Date: 2019-04-16
• Subjects: IL-10 (interleukin-10) -- CTCL (cutaneous T-cell lymphoma) -- macrophages -- tumor immunology; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1516037
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: A crucial question pertains to a role of IL-10 as a tumorigenic factor, or just a marker of advanced disease in cutaneous T-cell lymphoma (CTCL). Herein, we measured significantly elevated IL-10 mRNA in a cohort of skin samples of patients with CTCL. Increased IL-10 was also detected in the tumor microenvironment of an established inflammation-dependent murine model of using MBL2 T lymphoma cells. Conditioned media from MBL2 cells was able to stimulate IL-10 production in bone marrow-derived macrophages in an IL-4-dependent manner. Implanted MBL2 T-cell lymphomas in IL-10KO mice were 50% smaller, accompanied by decreased numbers of infiltrating macrophages and reduced efficiency of M2-polarization compared with wild-type mice. With anti-IL-10R mAb treatment, both wild-type tumor-bearing mice and IL-10KO mice exhibited a further growth inhibition. Our data indicate that targeting IL-10 signaling with neutralizing antibodies to IL-10 or its receptor may have a great potential for advanced CTCL therapy.